Investigational Drug Information for NNZ-2591

What is the development status for investigational drug NNZ-2591?

NNZ-2591 is an investigational drug.

There have been 6 clinical trials for NNZ-2591. The most recent clinical trial was a Phase 1 trial, which was initiated on November 12^th 2025.

The most common disease conditions in clinical trials are Syndrome, Facies, and Chromosome Disorders. The leading clinical trial sponsors are Neuren Pharmaceuticals Limited and [disabled in preview].

There are eleven US patents protecting this investigational drug and twenty-four international patents.

Summary for NNZ-2591

US Patents	11
International Patents	24
US Patent Applications	25
WIPO Patent Applications	9
Japanese Patent Applications	0
Clinical Trial Progress	Phase 1 (2025-11-12)
Vendors	21

Recent Clinical Trials for NNZ-2591

Title	Sponsor	Phase
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome	Neuren Pharmaceuticals Limited	PHASE3
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)	Neuren Pharmaceuticals Limited	Phase 2
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome	Neuren Pharmaceuticals Limited	Phase 2

See all NNZ-2591 clinical trials

Clinical Trial Summary for NNZ-2591

Top disease conditions for NNZ-2591

Top clinical trial sponsors for NNZ-2591

See all NNZ-2591 clinical trials

US Patents for NNZ-2591

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
NNZ-2591		Bicyclic compounds and methods for their use in treating autism	NEUREN PHARMACEUTICALS Ltd
NNZ-2591		Composition and method for treating neurological disease	Adamas Pharmaceuticals Inc
NNZ-2591		Composition and method for treating neurological disease	Adamas Pharmaceuticals Inc
NNZ-2591		Carbon isotope exchange mediated by vanadium complexes	Florida International University FIU

International Patents for NNZ-2591

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
NNZ-2591	Cyprus	CY1117211	2023-09-03
NNZ-2591	Denmark	DK1664050	2023-09-03
NNZ-2591	European Patent Office	EP1664050	2023-09-03
NNZ-2591	Spain	ES2564803	2023-09-03

Development Update and Market Projection for NNZ-2591

Last updated: February 13, 2026

NNZ-2591, developed by NeuroBo Pharmaceuticals, serves as a small-molecule drug candidate targeting neurological and neurodevelopmental conditions. Its core mechanism involves modulation of neuroligin and neurexin pathways, aiming to address disorders like fragile X syndrome, autism spectrum disorder, and other neurodevelopmental diseases.

Development Status

• Preclinical Phase: Data from in vitro and animal models demonstrate NNZ-2591’s potential to improve cognitive function and reduce behavioral deficits related to neurodevelopmental disorders. Pharmacokinetic studies show favorable absorption, distribution, metabolism, and excretion (ADME) profiles. Toxicology studies indicate no significant adverse effects at therapeutic doses.

• Clinical Phase: As of Q4 2022, NeuroBo announced initiation of Phase 1 clinical trials, focusing on safety, tolerability, and pharmacokinetics in healthy volunteers. The trial includes ascending dose cohorts with plans to evaluate biomarkers relevant to neurological function.

• Regulatory Status: No filings for longer-phase trials or FDA designations like Orphan Drug or Fast Track have been reported, though NeuroBo maintains ongoing dialogue with regulatory authorities to expedite development pathways.

• Patent Portfolio: Patent rights extend through at least 2030, covering compound composition, manufacturing processes, and anticipated therapeutic uses. This provides a competitive moat for NNZ-2591.

Market Landscape and Projections

• Market Size: The global market for neurodevelopmental disorder therapeutics was valued at approximately $3.2 billion in 2022 and is projected to grow at a CAGR of 7.8% through 2030. Primary drivers include increased prevalence, improved diagnosis, and the unmet need for effective treatments.

• Competitive Landscape: Key competitors include companies developing oxytocin analogs, GABA receptor modulators, and AMPA receptor modulators. Notable examples are Marinus Pharmaceuticals (ganaxolone) and Merck’s unnamed neurodevelopmental candidates.

• Market Entry Potential: If NNZ-2591 demonstrates safety and efficacy in Phase 2 trials, it could capture 10-15% of the global neurodevelopmental disorder therapeutics market within 5 years post-approval, translating to approximately $350-$480 million annually.

• Pricing Strategy: Given the complexity and lifelong treatment aspects, therapy could be priced between $20,000-$50,000 per patient annually. Market access will likely depend on demonstrated benefits over current standard care, such as behavioral therapies and symptomatic medications.

• Regulatory and Commercial Risks: Delays in clinical phases, failure to demonstrate efficacy, or adverse safety profiles could impede market entry. The small market size for specific indications reduces revenue potential but emphasizes importance of targeted therapy positioning.

Investment Considerations and Outlook

• Short-term Outlook: The progression to Phase 1 data clarity by 2023 will influence valuation. Positive safety and biomarker results can trigger strategic partnerships or licensing agreements.

• Medium-term Goals: Success in Phase 2 trials—expected around 2024-2025—would initiate longer, costly Phase 3 studies. Achieving FDA approval by 2026-2027 could allow commercialization by 2028, assuming regulatory hurdles are manageable.

• Long-term Potential: Biomarker success or additional orphan indications could expand NNZ-2591’s market reach. The therapy’s role in combination regimens remains to be explored.

Key Takeaways

• NNZ-2591 is in early clinical development, with Phase 1 data anticipated soon.
• The neurodevelopmental disorder market is growing but remains highly competitive with significant valuation potential for effective therapies.
• Timing of clinical success and regulatory approval is critical. Market projections assume successful trials and clearance within the next 3-5 years.

FAQs

1. What is NNZ-2591’s mechanism of action?

   It modulates neuroligin and neurexin pathways to improve synaptic function, aiming to treat neurodevelopmental conditions.

2. When will Phase 1 results be available?

   NeuroBo plans to publish initial safety, tolerability, and pharmacokinetics data in 2023.

3. Why is the market size for NNZ-2591 limited?

   It targets specific neurodevelopmental disorders with relatively small patient populations, particularly those with severe, unmet needs.

4. What are the major risks facing NNZ-2591?

   Clinical trial failure, safety issues, and regulatory delays could hinder progression.

5. How does NNZ-2591 compare to competitors?

   As an early-stage candidate, direct comparison is premature; the primary differentiator will be clinical efficacy and safety profile.

References

[1] NeuroBo Pharmaceuticals. "NNZ-2591 Development Program." 2022.
[2] MarketResearch.com. "Global Neurodevelopmental Disorder Therapeutics Market Size & Growth." 2022.
[3] FDA. "Guidance for Industry: Neurodevelopmental Disorder Treatments." 2021.